Grade @ or worse adverse events seen in more than @ % of patients were neutropenia ( @ -LSB- @ % -RSB- of @ patients in the ramucirumab group vs @ -LSB- @ % -RSB- of @ in the placebo group , with febrile neutropenia incidence of @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , hypertension ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , diarrhoea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and fatigue ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .